Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Cybin ( (HELP) ) is now available.
On February 10, 2026, Cybin Inc., dba Helus Pharma, announced a major leadership change with the appointment of industry veteran Michael Cola as Chief Executive Officer, effective immediately. The material change report detailing this move was formally filed on February 18, 2026, underscoring the strategic importance of the transition.
Helus framed Cola’s arrival as pivotal to steering its mental health pipeline through upcoming clinical and corporate milestones, drawing on his three decades of experience in neuroscience, rare disease and specialty pharmaceuticals. His track record at Shire, Astra-Merck, AstraZeneca, Avalo Therapeutics and various board roles suggests an emphasis on scaling CNS franchises, capital formation and value creation, signaling a more aggressive growth and commercialization push for the company.
The most recent analyst rating on (HELP) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Cybin stock, see the HELP Stock Forecast page.
More about Cybin
Cybin Inc., which now does business as Helus Pharma, operates in the biopharmaceutical sector with a focus on next-generation mental health therapies. The Toronto-based company is advancing a pipeline targeting central nervous system disorders, positioning itself around innovative CNS assets intended to reach key clinical and corporate value-inflection milestones.
Average Trading Volume: 659,424
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.41M
Find detailed analytics on HELP stock on TipRanks’ Stock Analysis page.